DK1306082T3 - Afmålte dosisinhalatorer under tryk og farmaceutiske aerosolformuleringer - Google Patents

Afmålte dosisinhalatorer under tryk og farmaceutiske aerosolformuleringer

Info

Publication number
DK1306082T3
DK1306082T3 DK02026980T DK02026980T DK1306082T3 DK 1306082 T3 DK1306082 T3 DK 1306082T3 DK 02026980 T DK02026980 T DK 02026980T DK 02026980 T DK02026980 T DK 02026980T DK 1306082 T3 DK1306082 T3 DK 1306082T3
Authority
DK
Denmark
Prior art keywords
under pressure
metered dose
aerosol formulations
dose inhalers
pharmaceutical aerosol
Prior art date
Application number
DK02026980T
Other languages
English (en)
Inventor
Frank E Blondino
Michael Brucato
Maria W Buenafe
Original Assignee
Ivax Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Research Inc filed Critical Ivax Research Inc
Application granted granted Critical
Publication of DK1306082T3 publication Critical patent/DK1306082T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
DK02026980T 1998-06-19 1999-06-18 Afmålte dosisinhalatorer under tryk og farmaceutiske aerosolformuleringer DK1306082T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/099,779 US6451285B2 (en) 1998-06-19 1998-06-19 Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
PCT/US1999/013863 WO1999065460A2 (en) 1998-06-19 1999-06-18 Pressurized metered dose inhalers and pharmaceutical aerosol formulations comprising a beta-agonist

Publications (1)

Publication Number Publication Date
DK1306082T3 true DK1306082T3 (da) 2004-06-01

Family

ID=22276581

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02026980T DK1306082T3 (da) 1998-06-19 1999-06-18 Afmålte dosisinhalatorer under tryk og farmaceutiske aerosolformuleringer
DK99931837T DK1085856T3 (da) 1998-06-19 1999-06-18 Tryksatte inhalatorer med afmålt dosis og farmaceutiske aerosolformuleringer, der omfatter en beta-agonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK99931837T DK1085856T3 (da) 1998-06-19 1999-06-18 Tryksatte inhalatorer med afmålt dosis og farmaceutiske aerosolformuleringer, der omfatter en beta-agonist

Country Status (23)

Country Link
US (2) US6451285B2 (da)
EP (2) EP1306082B1 (da)
JP (1) JP2002518100A (da)
KR (1) KR20010053025A (da)
CN (2) CN1154477C (da)
AR (1) AR018891A1 (da)
AT (2) ATE250409T1 (da)
AU (1) AU762927B2 (da)
BR (1) BR9912170A (da)
CA (1) CA2335303A1 (da)
CO (1) CO5031245A1 (da)
DE (2) DE69915144T2 (da)
DK (2) DK1306082T3 (da)
ES (2) ES2205848T3 (da)
HU (1) HUP0102468A3 (da)
IL (1) IL140340A0 (da)
NO (1) NO20006466L (da)
PL (1) PL345399A1 (da)
PT (2) PT1085856E (da)
RU (1) RU2214230C2 (da)
SK (1) SK19442000A3 (da)
WO (1) WO1999065460A2 (da)
ZA (1) ZA200007455B (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
HU230804B1 (hu) 2000-05-22 2018-06-28 Chiesi Farmaceutici S.P.A Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
US20030072717A1 (en) * 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
ATE267591T1 (de) * 2001-07-02 2004-06-15 Chiesi Farma Spa Optimierte tobramycin-formulierung zur aerosolbildung
US20030178022A1 (en) * 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
DE10205087A1 (de) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln
JP2005523905A (ja) * 2002-03-01 2005-08-11 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ホルモテロール（ｆｏｒｍｏｔｅｒｏｌ）超微細調合物
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
MXPA05001903A (es) * 2002-08-21 2005-04-28 Norton Healthcare Ltd Composicion para inhalacion.
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
WO2007008427A2 (en) * 2005-07-08 2007-01-18 Xemplar Pharmaceuticals, Llc Aerosol compositions and methods
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US9463161B2 (en) * 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
US20120272951A1 (en) 2009-12-16 2012-11-01 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
EP3383366B1 (en) 2015-12-04 2020-03-25 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
CN109715148A (zh) 2016-09-19 2019-05-03 墨西哥氟石股份公司 药物组合物
CN113288869A (zh) 2016-09-19 2021-08-24 墨西哥氟石股份公司 药物组合物
CN114515284A (zh) 2016-09-19 2022-05-20 墨西哥氟石股份公司 药物组合物
CN109464429B (zh) * 2018-12-13 2021-04-27 上海方予健康医药科技有限公司 一种吸入压力定量气雾剂药物组合物及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE556587A (da) 1957-01-31 1957-04-11
NL7708731A (nl) 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
WO1992000061A1 (en) 1990-06-29 1992-01-09 Fisons Plc Pressurised aerosol compositions
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
CA2094266C (en) 1990-10-18 1999-06-01 Robert K. Schultz Aerosol formulations of beclomethasone-17,21-dipropionate
US5190029A (en) 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
WO1992022286A1 (en) 1991-06-12 1992-12-23 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
DE4123663A1 (de) 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Aerosol-zubereitung und verwendung eines treibmittels dafuer
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
AU663906B2 (en) * 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
NZ246421A (en) 1991-12-18 1996-05-28 Minnesota Mining & Mfg Aerosol formulation containing a drug and a propellant and which is substantially free of surfactant
JP3342484B2 (ja) 1991-12-18 2002-11-11 アストラ・アクチエボラーグ 新規な配合
ATE137666T1 (de) 1991-12-31 1996-05-15 Hoechst Ag Medizinische aerosolformulierung
US5492688A (en) 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
US5508023A (en) 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
NZ298169A (en) 1994-12-22 1999-09-29 Astra Ab Aerosol drug formulation; comprises hydrofluoroalkane propellant, medicament for inhalation and a surfactant
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
CA2273835A1 (en) 1996-12-04 1998-06-11 Bioglan Ireland (R & D) Limited Pharmaceutical compositions and devices for their administration
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol

Also Published As

Publication number Publication date
KR20010053025A (ko) 2001-06-25
NO20006466L (no) 2001-02-16
BR9912170A (pt) 2001-10-23
EP1085856A2 (en) 2001-03-28
PT1306082E (pt) 2004-05-31
JP2002518100A (ja) 2002-06-25
DE69911602D1 (de) 2003-10-30
DK1085856T3 (da) 2003-12-08
WO1999065460A3 (en) 2000-04-27
CN1522692A (zh) 2004-08-25
ES2215153T3 (es) 2004-10-01
HUP0102468A3 (en) 2002-12-28
DE69915144D1 (de) 2004-04-01
HUP0102468A2 (hu) 2002-03-28
AU762927B2 (en) 2003-07-10
US20020018753A1 (en) 2002-02-14
CN1154477C (zh) 2004-06-23
CA2335303A1 (en) 1999-12-23
DE69915144T2 (de) 2004-12-09
CO5031245A1 (es) 2001-04-27
AU4825999A (en) 2000-01-05
EP1085856B1 (en) 2003-09-24
ATE260093T1 (de) 2004-03-15
ZA200007455B (en) 2002-06-13
SK19442000A3 (sk) 2001-09-11
ATE250409T1 (de) 2003-10-15
US20030077230A1 (en) 2003-04-24
AR018891A1 (es) 2001-12-12
EP1306082B1 (en) 2004-02-25
IL140340A0 (en) 2002-02-10
RU2214230C2 (ru) 2003-10-20
PL345399A1 (en) 2001-12-17
DE69911602T2 (de) 2004-07-01
CN1310611A (zh) 2001-08-29
ES2205848T3 (es) 2004-05-01
EP1306082A1 (en) 2003-05-02
WO1999065460A2 (en) 1999-12-23
NO20006466D0 (no) 2000-12-18
PT1085856E (pt) 2004-01-30
US6451285B2 (en) 2002-09-17

Similar Documents

Publication Publication Date Title
DK1306082T3 (da) Afmålte dosisinhalatorer under tryk og farmaceutiske aerosolformuleringer
HUS1800032I1 (hu) Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
DE69942896D1 (de) Druckdosierinhalatoren
NO307864B1 (no) Farmasøytisk aerosolformulering, boks og doseringsinhalator
DK0883415T3 (da) Inhalator til pulverformigt medikament
PL348809A1 (en) Pharmaceutical aerosol formulations containing fluoroalkanes, budesonide and formoterol
DE69904312T2 (de) Pharmazeutische aerosolformulierung
ATE236617T1 (de) Aerosol-arzneiformulierungen
DK0934057T3 (da) Medicinske aerosolformuleringer med formoterol
HUP0200066A3 (en) Pharmaceutical aerosol formulations containing fluoroalkanes and budesonide
NO20026055L (no) Farmasöytiske komponenter innbefattende humant paratyreoideahormon og farmasöytiske sammenstninger for nasal administrering inneholdendekomponentene